NCT02135718 - ELLIPTA™ vs. MDI Inhaler Preference Study, in Adult Subjects With Asthma | Biotech Hunter

Enrollment

288

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

July 31, 2014

Study Completion Date

July 31, 2014

Conditions

Asthma

Interventions

DEVICE

ELLIPTA inhaler

ELLIPTA inhaler, placebo DPIwith 30 doses (2 strips with 30 blisters per strip containing lactose in strip first strip and Lactose blended with magnesium stearate in second strip)

DEVICE

Placebo Inhalation Aerosol (MDI)

Placebo inhaler MDI will be supplied containing aerosol propellant

Trial Locations (15)

20814

GSK Investigational Site, Bethesda

21236

GSK Investigational Site, Baltimore

29118

GSK Investigational Site, Orangeburg

29303

GSK Investigational Site, Spartanburg

33180

GSK Investigational Site, Aventura

44718

GSK Investigational Site, Canton

55402

GSK Investigational Site, Minneapolis

55441

GSK Investigational Site, Plymouth

78229

GSK Investigational Site, San Antonio

78750

GSK Investigational Site, Austin

92083

GSK Investigational Site, Vista

92647

GSK Investigational Site, Huntington Beach

92663

GSK Investigational Site, Newport Beach

97504

GSK Investigational Site, Medford

02747

GSK Investigational Site, North Dartmouth